NFX vs. FAB, CIZ, HEMO, APTA, GENF, EVG, MTFB, DEST, ROQ, and VAL
Should you be buying Nuformix stock or one of its competitors? The main competitors of Nuformix include Fusion Antibodies (FAB), Cizzle Biotechnology (CIZ), Hemogenyx Pharmaceuticals (HEMO), Aptamer Group (APTA), Genflow Biosciences (GENF), Evgen Pharma (EVG), Motif Bio (MTFB), Destiny Pharma (DEST), Roquefort Therapeutics (ROQ), and ValiRx (VAL). These companies are all part of the "biotechnology" industry.
Nuformix vs.
Fusion Antibodies (LON:FAB) and Nuformix (LON:NFX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.
Nuformix has a consensus target price of GBX 293, suggesting a potential upside of 284,366.02%. Given Nuformix's stronger consensus rating and higher possible upside, analysts clearly believe Nuformix is more favorable than Fusion Antibodies.
Nuformix received 15 more outperform votes than Fusion Antibodies when rated by MarketBeat users. However, 68.35% of users gave Fusion Antibodies an outperform vote while only 66.99% of users gave Nuformix an outperform vote.
Fusion Antibodies has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, Nuformix has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500.
In the previous week, Fusion Antibodies had 1 more articles in the media than Nuformix. MarketBeat recorded 1 mentions for Fusion Antibodies and 0 mentions for Nuformix. Fusion Antibodies' average media sentiment score of 0.00 equaled Nuformix'saverage media sentiment score.
Nuformix has a net margin of 0.00% compared to Fusion Antibodies' net margin of -195.95%. Nuformix's return on equity of -5.68% beat Fusion Antibodies' return on equity.
Nuformix has lower revenue, but higher earnings than Fusion Antibodies. Nuformix is trading at a lower price-to-earnings ratio than Fusion Antibodies, indicating that it is currently the more affordable of the two stocks.
21.0% of Fusion Antibodies shares are owned by institutional investors. Comparatively, 0.1% of Nuformix shares are owned by institutional investors. 11.4% of Fusion Antibodies shares are owned by company insiders. Comparatively, 12.4% of Nuformix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Nuformix beats Fusion Antibodies on 11 of the 16 factors compared between the two stocks.
Get Nuformix News Delivered to You Automatically
Sign up to receive the latest news and ratings for NFX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuformix Competitors List
Related Companies and Tools
This page (LON:NFX) was last updated on 4/24/2025 by MarketBeat.com Staff
Buy NFX Stock Free NFX Stock Alerts